Rheumatoid Arthritis Drug Trials for Tasocitinib aka CP-690550
Phase 3 Rheumatoid Arthritis drug trials mean more widespread testing of Tasocitinib aka CP-690550 Last night, I learned some exciting news about a new kind of Rheumatoid Arthritis drug in development...
View ArticleTofacitinib / CP-690550 aka Tasocitinib Succeeds in Pfizer’s 2nd Phase 3 Trial
A new name and new milestone for tofacitinib Pfizer announced Friday that CP-690550 tofacitinib (formerly tasocitinib) met its goals in its second phase three clinical trial for moderate to severe...
View ArticleNew Way to Report Response in RA Clinical Trials?
Untangling a possible replacement for the “familiar” ACR 20 describing treatment response in clinical trials for Rheumatoid Arthritis Special thanks to Jay Sprinkel for assistance with this post....
View ArticlePfizer’s JAK inhibitor Tofacitinib EMA Application Validated
Pfizer JAK-3 press release “Pfizer Announces European Medicines Agency Acceptance Of Regulatory Submission For Tofacitinib For The Treatment Of Rheumatoid Arthritis: Pfizer Inc. (NYSE:PFE) announced...
View ArticleAttending an FDA Hearing for Pfizer’s JAK: Tofacitinib CP-690550
Three years ago, one of the first friends I made through my blog was Angie. She got into a Pfizer clinical trial for tofacitinib (then called tasocitinib). She sent me some info about the trial, but my...
View ArticleFDA Arthritis Advisory Committee Hearing for Pfizer’s RA JAK: Tofacitinb
Advisory Committee hearing feed link My daughter Katie Beth and I are in Washington, DC for the final FDA Arthritis Advisory Committee (AAC) hearing about Pfizer’s JAK, tofacitinib. Early in the...
View ArticleAftermath of the FDA Vote on Pfizer’s RA JAK Inhibitor, Tofacitinib
After the tofacitinib FDA hearing, the votes are in, false perceptions persist, and patients still need relief. Some estimate that tofacitinib could be approved by the US FDA within a few months after...
View ArticleMind-boggling! – Aftermath of Tofacitinib FDA Hearing Part 2
After the FDA Arthritis Advisory Committee (AAC) hearing earlier this month for Pfizer’s new oral treatment for RA, tofacitinib, we looked at the four distinct votes of the AAC and some of the ways...
View ArticleRA News: Pfizer Pill Beats Methotrexate, Alcohol Reduces RA Risk, Periodontal...
Pfizer oral JAK “superior” to methotrexate Pfizer released a statement about their two year study, ORAL Start, which puts their new oral JAK treatment for Rheumatoid Arthritis directly up against...
View Article
More Pages to Explore .....